Article Text

PDF

O1 Is pre-exposure prophylaxis for hiv prevention cost-effective in men who have sex with men who engage in condomless sex in the uk?
  1. Valentina Cambiano1,
  2. Alec Miners2,
  3. David Dunn3,
  4. Sheena McCormack3,
  5. Noel Gill4,
  6. Anthony Nardone4,
  7. Monica Desai4,
  8. Gus Cairns5,
  9. Alison Rodger1,
  10. Andrew Phillips1
  1. 1University College London, London, UK
  2. 2London School of Hygiene and Tropical Medicine, London, UK
  3. 3MRC Clinical Trials Unit at UCL, London, UK
  4. 4Public Health England, London, UK
  5. 5NAM, London, UK

Abstract

Background Pre-exposure prophylaxis (PrEP) is highly protective against sexual acquisition of HIV among men having sex with men (MSM). The cost-effectiveness of PrEP will play a major role in deciding whether the NHS should introduce PrEP.

Aim To evaluate the cost-effectiveness of introducing PrEP among MSM in the UK.

Methods An individual-based dynamic stochastic model calibrated to the HIV epidemic among MSM in the UK was used. It was assumed that, from 2016, 50% of people who tested negative for HIV and who had periods of condomless sex with a long-term or casual partners would use PrEP during such periods. While on PrEP men would be tested three-monthly and PrEP discontinued if diagnosed HIV-positive or if not engaging in condomless sex for that three-month period (and restarting PrEP if again engaging in condomless sex).

Results Preliminary results indicate that the introduction of PrEP would lead to a gain in quality-adjusted life years. If current costs of antiretrovirals and PrEP are assumed for the next 30 years (as is generally regarded as good practice in the base cases analysis) PrEP introduction is not cost-effective. However, when considering likely reductions in costs of antiretrovirals and PrEP, due to the use of generic drugs, PrEP would likely be cost-effective.

Conclusion Our preliminary evaluation suggests that the use of PrEP for MSM during periods of condomless sex is not cost effective at current antiretroviral prices, but it would become cost-effective if drug prices are reduced after patent expiry date.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.